you’re right. Deferred is a big difference to rejection so the application is still up for consideration. They must have said yes to a lot of companies already. Like others, I would have thought since they are well established in the US they would be able to navigate that space with an advantage.
Ann: Deferral of FDA consideration of enforcement discretion, page-18
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.79 |
Change
0.160(2.41%) |
Mkt cap ! $4.908B | |||
| Open | High | Low | Value | Volume |
| $6.60 | $6.82 | $6.59 | $20.55M | 3.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14149 | $6.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.80 | 15600 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.81 |
Change
0.160 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $6.60 | $6.82 | $6.60 | 946404 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| A2M (ASX) Chart |